Investors & Media

Nov 19, 2019 /

Nov 19, 2019 / Nov 19, 2019 /

Recent News

11/14/19

BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019
LAVAL, Quebec --(BUSINESS WIRE)--Nov. 14, 2019-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported...
Read More
11/13/19

BELLUS Health to Present at Jefferies Global Healthcare Conference in London
LAVAL, Quebec --(BUSINESS WIRE)--Nov. 13, 2019-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
9/17/19

BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 17, 2019-- BELLUS Health Inc. (“ BELLUS Health” or the “Company”) (Nasdaq: BLU; TSX: BLU), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today...
Read More